These results suggest that the combination of ponatinib and CD19@NP/17-DMAG not only triggers an anti-leukemia T-cell response but also promotes T-cell memory development, enhancing long-term immune surveillance against leukemia. The gene discussed is CD19; the disease is leukemia.